Seaport Therapeutics, Inc. (SPTX)
NASDAQ: SPTX · Real-Time Price · USD
16.85
-0.30 (-1.75%)
Oct 13, 2026, 10:25 AM EDT - Market open
Seaport Therapeutics Employees
Seaport Therapeutics had 58 employees as of June 30, 2026. That makes Seaport Therapeutics the 34,289th largest employer in the world and 4,577th in the United States.
Employees
58
Change
n/a
Growth
n/a
Revenue / Employee
n/a
Profits / Employee
-$2,322,190
Market Cap
901.99M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Jun 30, 2026 | 58 | - | - |
| Mar 31, 2026 | 58 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Immatics | 704 |
| MeiraGTx Holdings | 393 |
| Kura Oncology | 260 |
| Alumis | 239 |
| Rigel Pharmaceuticals | 174 |
| MoonLake Immunotherapeutics | 130 |
| Cullinan Therapeutics | 109 |
| Adlai Nortye Group | 109 |
SPTX News
- 3 days ago - PureTech Founded Entity Seaport Therapeutics Presents Additional Pharmacokinetic Data from Phase 1 Clinical Trial of GlyphAgo™ at the 39th European College of Neuropsychopharmacology (ECNP) Congress - Business Wire
- 4 days ago - Seaport Therapeutics presents additional PK data from Phase 1 GlyphAgo trial - TheFly
- 4 days ago - Seaport Therapeutics Presents Additional Pharmacokinetic Data from Phase 1 Clinical Trial of GlyphAgo™ at the 39th European College of Neuropsychopharmacology (ECNP) Congress - Business Wire
- 5 days ago - PureTech Founded Entity Seaport Therapeutics Announces First Patient Dosed in Phase 2a Clinical Trial Evaluating GlyphAgo™ in Patients with Generalized Anxiety Disorder and Sleep Disturbance - Business Wire
- 6 days ago - Seaport announces first patient dosed in Phase 2a trial of GlyphAgo - TheFly
- 6 days ago - Seaport Therapeutics Announces First Patient Dosed in Phase 2a Clinical Trial Evaluating GlyphAgoTM in Patients with Generalized Anxiety Disorder and Sleep Disturbance - Business Wire
- 18 days ago - Seaport Therapeutics initiated with a Strong Buy at Raymond James - TheFly
- 20 days ago - Seaport Therapeutics Transcript: TD Cowen 6th Annual Novel Mechanisms in Neuropsychiatry Summit - Transcripts